FindTrial
Sign In

Post-marketing surveillance of administration of botulinum toxin type B(NerBloc)-investigation of the clinical condition in patients with changing from botulinum toxin type A

Post-marketing surveillance of administration of botulinum toxin type B(NerBloc)-investigation of the clinical condition in patients with changing from botulinum toxin type A (Stydy NB02T)

Status
Unknown
Phases
Unknown
Study type
Observational
Source
JPRN
Registry ID
JPRN-jRCT1080222128
Enrollment
150
Registered
2013-06-28
Start date
2013-06-28
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

cervical dystonia

Interventions

investigational material(s) Generic name etc : botulinum toxin type B(NerBloc ) INN of investigational material : Therapeutic category code : 122 Skeletal muscle relaxants Dosage and Administration f

Sponsors

Eisai Co., Ltd.
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Patient with cervical dystonia who was treated by botulinum toxin type A in the past. Patient who was enrolled in Study NB01S and was evaluated by Toronto Western Spasmodic Torticollis Scale (TWSTRS) at the first injection of NerBloc.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

MeasureTime frame
Whole improvement level using Toronto Western Spasmodic Torticollis Scale (TWSTRS) Toronto Western Spasmodic Torticollis Scale (TWSTRS)—

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026